Dupixent was approved for treating COPD with raised blood eosinophils in the EU in July 2024. Dupixent was also approved for the COPD indication in China last week. Sanofi’s stock has gained 16.0% so ...

Rate this content's potential impact on patient outcomes Submit Rating Thank you! Please share some more information on the ...

Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, ...

USA Today reports on how the former president benefitted after a diagnosis that just years prior would have been terminal. Cancer therapies have enabled him to celebrate his 100th birthday this week.

In a 3-year extension of the pivotal trials that provided lebrikizumab with an indication for atopic dermatitis, the response ...

Adding daratumumab to lenalidomide in maintenance therapy for multiple myeloma significantly reduced rates of minimal ...

AbbVie Humira, Pfizer/BioNTech COVID-19 shot may not make top 10 pharma drugs in 2024, with Novo Nordisk Ozempic and ...

Bristol Myers gains FDA approval for a new schizophrenia drug. HHS declares a health emergency in Georgia due to Hurricane ...

This summary of current health news includes FDA approvals for new drugs by Bristol Myers and GE HealthCare, public health ...

The U.S. FDA has approved Cobenfy, a dual M1/M4 muscarinic agonist that offers a fundamentally different approach to treating schizophrenia. The fixed dose combination of xanomeline-trospium is the ...

Health-care companies ticked up, but lost ground during a generally positive week for the stock market amid fears about the implications of a tight presidential race for health-care regulation.